ACADIA Pharmaceuticals (NASDAQ:ACAD) Director Torsten Rasmussen sold 30,000 shares of the company’s stock on the open market in a transaction dated Friday, April 4th. The stock was sold at an average price of $21.98, for a total transaction of $659,400.00. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares after opening at $22.00 moved to $22.14 on last trade day and at the end of the day closed at $20.04. Company price to sales ratio in past twelve months was calculated as 1776.27 and price to cash ratio as 10.52. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) showed a negative weekly performance of -13.10%.
Cell Therapeutics Inc (NASDAQ:CTIC)’s shares dropped 1.49% to $3.31. Cell Therapeutics to benefit from Geron troubles, says Roth Capital. After Geron’s (GERN) telomerase inhibitor for myelofibrosis and other settings was put on full clinical hold due to potential liver injury, Roth Capital thinks that the competitive positioning of CTIC’s myelofibrosis treatment, Pacritinib, has improved. Cell Therapeutics Inc (NASDAQ:CTIC) shares fell -8.33% in last trading session and ended the day on $3.19. CTIC return on equity ratio is recorded as -295.00% and its return on assets is -77.80%. Cell Therapeutics Inc (NASDAQ:CTIC) yearly performance is 175.00%.
Novavax Inc. (NASDAQ:NVAX)’s annual revenue grew 62-fold over the last five years; its revenue grew 92% in 4Q13. For full-year 2014, revenue is expected to grow 77.7%. Novavax, Inc. (NASDAQ:NVAX) shares moved down -7.34% in last trading session and was closed at $4.04 while trading in range of $4.00 – $4.44 – Novavax, Inc. (NASDAQ:NVAX) year to date (YTD) performance is -21.09%.
InterMune, Inc. (NASDAQ:ITMN) announced that it has agreed to sell 7,500,000 shares of its common stock at a price to the public of $32.75 per share in an underwritten public offering. InterMune estimates net proceeds from the offering to be approximately $233.0 million. InterMune Inc (NASDAQ:ITMN) weekly performance is -10.93%. On last trading day company shares ended up $28.84. InterMune Inc (NASDAQ:ITMN) distance from 50-day simple moving average (SMA50) is 12.56%. Analysts mean target price for the company is $39.21.
Leave a Reply